Re: Thoughts on ZCC
in response to
by
posted on
Sep 05, 2021 05:42PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
KOO - ZEL is an wholly owned operating subsidiary of ZCC. ZEL can be sold off anytime without affecting ZCC's status. We have been around this corner a number of times already KOO.
If there is a sale of ZEL, each shareholder could be issued new shares of ZEL or any other entity that ZEL may be vended into and then immediately sold. The process in theory would give all shareholders a capital gain on the sale of ZEL and retention of ZCC which again in theory would pay a royalty to the shareholders if and when sales status is ever achieved from any products derived from either RVX or ZEL. IMO at least one product and potentially more will hit the market sometime before their patents or I expire.
tada